Journal List > Korean J Schizophr Res > v.18(1) > 1122202

TOOLS
Lee, Lee, Koo, and Park: Suicide in Patients with Schizophrenia : A Review on the Findings of Recent Studies
Original Article

Korean J Schizophr Res 2015;18(1):5-9.

Published online: 17 January 2015

DOI: https://doi.org/10.16946/kjsr.2015.18.1.5

Suicide in Patients with Schizophrenia : A Review on the Findings of Recent Studies

Hoseon Lee, MD1, Kounseok Lee, MD1, Jae-Woo Koo, MD2, Seon-Cheol Park, MD, PhD2,

1Department of Psychiatry, St. Andrew's Neuropsychiatric Hospital, Icheon, Korea

2Department of Psychiatry, Yong-In Mental Hospital, Yongin, Korea

Address for correspondence: Seon-Cheol Park, Department of Psychiatry, Yong-In Mental Hospital, 940 Jungbu-daero, Giheung-gu, Yongin 446-769, Korea Tel: 031-288-0203, Fax: 031-288-0184 E-mail: cogito-ergo-sum@hanmail.net

본 논문의 내용 중 일부는 2014년 대한신경정신의학회 추계학술대회에서 구연 되었음.

      Revised 22 August 20142 December 2014       Accepted 3 December 2014

Copyright © 2015 Korean Society for Schizophrenia Research

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The suicide risk of patients with schizophrenia is about 8.5-fold greater than that of the general population. Since 4-13% of patients with schizophrenia commit suicide, and 25-50% attempt suicide at least once during their lifetime, suicide can be a main cause of their higher mortality rate as compared with that of the general population. While evidence suggests that previous depressive disorders, previous suicide attempts, drug misuse, agitation or motor restlessness, fear of mental disintegration, poor adherence to treatment, and recent loss of another person are associated with the increased risk of suicide in schizophrenia, hallucinations have been associated with decreased suicide risk. Despite there being at least modest evidence suggesting that antipsychotics protect against suicidal risk, clozapine has been shown to be the most favorable second-generation antipsychotic for preventing suicide in patients with schizophrenia. In addition, selective serotonin receptor inhibitors can ameliorate suicidal ideation in schizophrenia. Furthermore, individual psychosocial interventions and psychotherapy, and reducing stigma, can be integral strategies for the prevention of suicide in schizophrenia. Further study is needed to identify the epidemiological characteristics and clinical correlates of suicide in Korean patients with schizophrenia, and provide an effective strategy for its prevention in Korea.

Keywords: Schizophrenia, Suicide, Clozapine, Prevention

REFERENCES

1). Bleuler E. Dementia praecox or the group of schizophrenias (trans. J. Zinkin). New york: International Universities Press;1950.
2). White J, Gray R, Jones M. The development of the serious mental illness physical Health Improvement Profile J Psychiatr Ment Health Nurs. 2009; 16:493–498.
3). Sartorius N, Jablensky A, Korten A, Ernberg G, Anker M, Cooper J. Early manifestations and first -contact incidence of schizophrenia in different cultures. A preliminary report on the initial evaluation phase of the WHO Collaborative Study on determinants of outcome of severe mental disorders. Psychol Med. 1986; 16:909–928.
4). Cohen L, Test M, Brown R. Suicide and Schizophrenia: data from a prospective community treatment study. Am J psychiatry. 1990; 147:602–607.
5). Roy A, Mazonson A, Pickar D. Attempted suicide in chronic schizophrenia. Br J Psychiatry. 1984. 303–306.
crossref
6). Caldwell C, Gotteman I. Schizophrenia: a high-risk factor for suicide: clues to risk reduction. Suicide Life-Threat Behav. 1992; 22:479–493.
7). Meltzer H, Fatemi H. Suicide in schizophrenia: the effect of clozapine. Clin Neuropharmacol. 1995; 18:18–24.
crossref
8). Clarke M, Whitty P, Browne S, Tigue OM, Kinsella A, Waddington J. Suicidality in first episode psychosis. Schizophr Res. 2006; 192:221–225.
crossref
9). Harvey S, Dean K, Morgan C, Walsh E, Demjaha A, Dazzan P. Selp-harm in first episode psychosis. Br J Psychiatry. 2008; 192:178–184.
10). Robinson J, Cotton S, Conus P, Schimmelmann B, McGorry P, Lambert M. Prevalence and predictors of suicide attempt in an incidence cohort of 661 young people with firstepisode psychosis. Aust N Z J Psychiatry. 2009; 43:149–157.
crossref
11). Bakst S, Rabinowitz J, Bromet E. Antecedents and patterns of suicide behavior in first-admission psychosis. Schizophr Bull. 2009; 36:880–889.
crossref
12). Palmer B, Pankratz V, Bostwick J. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005; 62:247–253.
13). Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. Journal of Psychopharmacology. 2010; 24:81–90.
14). Saha S, Chant D, McGrath J. A systematic Review of Mortality in Schizophrenia. Arch Gen Psychiatry. 2007; 64:1123–1131.
crossref
15). Bushe C, Taylor M, Haukka J. Mortality in schizophrenia: a measurable clinical endpoint. Journal of Psychopharmacology. 2010; 24:17–25.
16). Hennen J, Baldessarini R. Suicidal risk during treatment with clozapine: a metaanalysis. Schizoohr Res. 2005; 73:139–145.
crossref
17). Dean C, Thuras P. Mortality and tardive dyskinesia: long term study using the US National Death Index. Br J Psychiatry. 2009; 194:360–364.
18). Tiihonen J, Wahlbeck K, Lonnqvist J, Klaukka T, Ioannidis J, Volav-ka J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational followup study. BMJ. 2006; 333:224.
crossref
19). Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Le-htinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry. 2006; 188:122–127.
20). Park S, Kim S, Hong J. Cause-Specific Mortality of Psychiatric Inpatients and Outpatients in a General Hospital in Korea. Asia-Pacific Journal of Public Health. 2012; XX:1–12.
crossref
21). Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm Country, Sweden. Schizophrenia Research. 2000; 45:21–28.
22). Brown S, Inskip H, Barraclough B. Cause of the excess mortality of schizophrenia. Britsh Journal of Psychiatry. 2000; 177:212–217.
23). Park S, Choi J, Yi K, Hong J. Suicidal mortality and risk factor in the 12 months after discharge from psychiatric inpatient care in Korea: 1989-2006. Psychiatry Research. 2013; 208:145–150.
24). Park JY, Moon KT, Chae YM, Jung SH. Effect of sociodemographic factors, Cancer, psychiatric disorder on suicide: Gender and age-specific patterns. J Prev Med Public Health. 2008; 41:51–60.
crossref
25). Gomez-Duran E, Martin-Fumado C, Hurtado-Ruiz G. Clinical and epidemiological aspects of suicide in patients with schizophrenia. Actas Esp Psiquiatr. 2012; 40:333–345.
26). Carlborg A, Winnerback K, Jonsson EG, Jokinen J, Nordstrom P. Suicide in schizophrenia. Expert Rev Neurother. 2010; 10:1153–1164.
crossref
27). Hawton K, Sutton L, Haw C, Sinclair J, Deeks J. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry. 2005; 187:9–20.
crossref
28). Tandon R. Suicidal Behavior in schizophrenia. Expert Rev Neurotherapeutics. 2005; 5:95–99.
crossref
29). Meltzer HY. Suicide and Schizophrenia: Clozapine and the Inter-SePT Study. J Clin Psychiatry. 1999; 60:47–50.
30). Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tan-skanen A, et al. 11-year followup of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). The Lancet. 2009; 374:620–627.
crossref
31). Lehman A, Lieberman J, Dixon L, McGlashan T, Miller A, Perkins D, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004; 161:1–56.
32). Pompili M, Girardi P, Ruberto A, Tatarelli R. Toward a New Prevention of Suicide in Schizophrenia. World J Biol Psychiatry. 2004; 5:201–210.
crossref
33). Kasckow J, Felmet K, Zisook S. Managing Suicide Risk in Patients with Schizophrenia. CNS Drugs. 2011; 25:129–143.
crossref
TOOLS
Similar articles